Stock Events

Stock Events

Gyre Therapeutics 

$6.9
0
-$0.03-0.43% Tuesday 04:00

Statistics

Day High
6.9
Day Low
6.9
52W High
-
52W Low
-
Volume
5
Avg. Volume
-
Mkt Cap
664.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jan 23
$0.12
Sep 22
$0.72
Aug 15
$0.28
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8MayExpected
Q3 2025
Q4 2025
Next
-0.07
-0.03
0.01
0.06
Expected EPS
-0.073333
Actual EPS
N/A

Financials

11.43%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
211.51MRevenue
24.17MNet Income

Analyst Ratings

$16.00Average Price Target
The highest estimate is 16.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GYRE.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Gyre Therapeutics' focus on gene therapy.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics competes in the gene editing space, directly challenging Gyre's approach to gene therapy with its own proprietary technologies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is in the competition due to its leading role in CRISPR-Cas9 gene editing, a technology that could be used in similar applications as Gyre's gene therapy platform.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement and gene therapy products, competing in the same niche as Gyre.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a competitor because of its focus on CRISPR gene editing for the treatment of genetic diseases, directly competing with Gyre's gene therapy approach.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing field, making it a competitor to Gyre Therapeutics by developing CRISPR-based therapies for genetic conditions.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals competes with Gyre by focusing on RNA interference (RNAi) for the treatment of genetic diseases, offering an alternative approach to gene therapy.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals is a competitor due to its work on RNA-targeted drug discovery and development, which could be used for similar therapeutic targets as Gyre's.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics is involved in the development of RNA-based and gene therapy treatments for rare genetic diseases, directly competing with Gyre Therapeutics in the gene therapy space.

About

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Show more...
CEO
ISIN
US4037831033

Listings

XNAS
US
GYRE
F
DE
L9S.F
BOATS
BOATS
GYRE.BOATS

0 Comments

Share your thoughts

FAQ

What is Gyre Therapeutics stock price today?▼
The current price of GYRE.BOATS is $6.9 USD — it has decreased by -0.43% in the past 24 hours. Watch Gyre Therapeutics stock price performance more closely on the chart.
What is Gyre Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gyre Therapeutics stocks are traded under the ticker GYRE.BOATS.
What is Gyre Therapeutics market cap?▼
Today Gyre Therapeutics has the market capitalization of 664.7M
When is the next Gyre Therapeutics earnings date?▼
Gyre Therapeutics is going to release the next earnings report on May 08, 2026.
What were Gyre Therapeutics earnings last quarter?▼
GYRE.BOATS earnings for the last quarter are -0.02 USD per share, whereas the estimation was 0.06 USD resulting in a -135.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Gyre Therapeutics revenue for the last year?▼
Gyre Therapeutics revenue for the last year amounts to 211.51M USD.
What is Gyre Therapeutics net income for the last year?▼
GYRE.BOATS net income for the last year is 24.17M USD.
Does Gyre Therapeutics pay dividends?▼
Yes, GYRE.BOATS dividends are paid quarterly. The last dividend per share was 0.12 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Gyre Therapeutics complete a stock split?▼
The last stock split for Gyre Therapeutics was on January 13, 2023 with a ratio of 2:1.